PÃ¥l Andre Holme

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4257428/publications.pdf

Version: 2024-02-01

60 papers	2,436 citations	430874 18 h-index	206112 48 g-index
62 all docs	62 docs citations	62 times ranked	3947 citing authors

#	Article	IF	Citations
1	Thrombosis and thrombocytopenia after HPV vaccination. Journal of Thrombosis and Haemostasis, 2022, 20, 700-704.	3.8	29
2	Bone mineral density in haemophilia â€“ a multicentre study evaluating the impact of different replacement regimens. Haemophilia, 2022, 28, 239-246.	2.1	2
3	Clinical outcome and adherence rate in Scandinavian patients with intermediateâ€intensity prophylaxis before and after the switch of standard halfâ€life FVIII products to BAY 81â€“8973. Haemophilia, 2022, 28, 223-229.	2.1	2
4	Anti-PF4/polyanion antibodies in COVID-19 patients are associated with disease severity and pulmonary pathology. Platelets, 2022, 33, 640-644.	2.3	7
5	Immune tolerance induction in the era of emicizumab â€“ still the first choice for patients with haemophilia A and inhibitors?. Haemophilia, 2022, 28, 215-222.	2.1	7
6	Platelet function testing: Current practice among clinical centres in Northern Europe. Haemophilia, 2022, 28, 642-648.	2.1	5
7	Surgical outcomes in patients with haemophilia A or B receiving extended halfâ€life recombinant factor VIII and IX Fc fusion proteins: Realâ€world experience in the Nordic countries. Haemophilia, 2022, 28, 713-719.	2.1	7
8	Comparison of freeâ€living physical activity measurements between ActiGraph GT3Xâ€BT and Fitbit Charge 3 in young people with haemophilia. Haemophilia, 2022, 28, .	2.1	6
9	Management of comorbidities in haemophilia. Haemophilia, 2021, 27, 37-45.	2.1	14
10	Investigation of the Optimal Dose aPCC in Reversing the Effect of Factor Xa Inhibitorsâ€”An In Vitro Study. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110211.	1.7	2
11	Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) study. Haemophilia, 2021, 27, e253-e259.	2.1	10
12	Treatment outcomes in persons with severe haemophilia B in the Nordic region: The Bâ€NORD study. Haemophilia, 2021, 27, 366-374.	2.1	6
13	Confirmed longâ€term safety and efficacy of prophylactic treatment with BAY 94â€“9027 in severe haemophilia A: final results of the PROTECT VIII extension study. Haemophilia, 2021, 27, e347-e356.	2.1	12
14	Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery. Haemophilia, 2021, 27, 519-530.	2.1	20
15	Bleeding phenotype of patients with moderate haemophilia A and B assessed by thromboelastometry and thrombin generation. Haemophilia, 2021, 27, 793-801.	2.1	1
16	The effect of emicizumab and bypassing agents in patients with hemophilia â€“ An in vitro study. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12561.	2.3	8
17	Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. New England Journal of Medicine, 2021, 384, 2124-2130.	27.0	1,155
18	Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia. European Heart Journal, 2021, 42, 4064-4072.	2.2	49

#	Article	IF	Citations
19	New Inhibitors in the Ageing Population: A retrospective, observational, cohort study of new inhibitors in older people with haemophilia. Thrombosis and Haemostasis, 2021, , .	3.4	0
20	Daratumumab As a Treatment for Adult Immune Thrombocytopenia: A Phase II Study with Safety Run-in (the DART Study). Blood, 2021, 138, 2088-2088.	1.4	3
21	The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis. Platelets, 2020, 31, 43-47.	2.3	3
22	Pharmacokinetics and pharmacodynamics of a recombinant fusion protein linking activated coagulation factor VII with human albumin (rVIIa-FP) in patients with congenital FVII deficiency. Hematology, 2020, 25, 17-25.	1.5	4
23	Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B â€“ The MoHem study. Haemophilia, 2020, 26, 891-897.	2.1	23
24	Macroscopic hematuria as a risk factor for hypertension in ageing people with hemophilia and a family history of hypertension. Medicine (United States), 2020, 99, e19339.	1.0	6
25	Hematuria in aging men with hemophilia: Association with factor prophylaxis. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 309-317.	2.3	7
26	Longâ€term outcomes of patients treated with rituximab as secondâ€line treatment for adult immune thrombocytopenia â€“ Followâ€up of the RITP study. British Journal of Haematology, 2020, 191, 460-465.	2.5	9
27	Real-World Clinical Management of Patients with Congenital Hemophilia and Inhibitors: Interim Analysis of the FEIBA Global Outcome Study (FEIBA GO). Blood, 2020, 136, 23-24.	1.4	0
28	Fixed doses of N8â€GP prophylaxis maintain moderateâ€toâ€mild factor VIII levels in the majority of patients with severe hemophilia A. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 542-554.	2.3	17
29	BAY 94â€9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results. Haemophilia, 2019, 25, 1011-1019.	2.1	23
30	The influence of rivaroxaban on markers of fibrinolysis and endothelial cell activation/injury in patients with venous thrombosis. Thrombosis Research, 2019, 177, 154-156.	1.7	1
31	Onceâ€weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8â€GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial). Haemophilia, 2019, 25, 373-381.	2.1	29
32	Evaluation of a standardized protocol for thrombin generation using the calibrated automated thrombogram: A Nordic study. Haemophilia, 2019, 25, 334-342.	2.1	12
33	Continuous infusion of simoctocog alfa in haemophilia A patients undergoing surgeries. Haemophilia, 2019, 25, 54-59.	2.1	4
34	Real-World Clinical Management of Patients with Hemophilia and Inhibitors: Effectiveness and Safety of aPCC in Patients with >18 Months' Follow-up in the FEIBA Global Outcome Study (FEIBA GO). Blood, 2019, 134, 2418-2418.	1.4	1
35	The Risk of Thromboembolism Associated with Treatment of ITP with Rituximab: Adverse Event Reported in Two Randomized Controlled Trials. Blood, 2019, 134, 4892-4892.	1.4	3
36	Rituximab Yielded a Significantly Longer Response Compared to Placebo in Steroid Free Population - a Post Hoc Analysis of the Ritp Study. Blood, 2019, 134, 2358-2358.	1.4	0

#	Article	IF	Citations
37	Continuous infusion of coagulation factor concentrates during intensive treatment. Haemophilia, 2018, 24, 24-32.	2.1	15
38	STIM1 R304W causes muscle degeneration and impaired platelet activation in mice. Cell Calcium, 2018, 76, 87-100.	2.4	21
39	The elevated prevalence of risk factors for chronic liver disease among ageing people with hemophilia and implications for treatment. Medicine (United States), 2018, 97, e12551.	1.0	12
40	Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series. Journal of Medical Case Reports, 2018, 12, 138.	0.8	15
41	Efficacy and Safety of Bay 94-9027 Is Sustained for 5 Years: Outcomes in 33 Patients in the Protect VIII Extension Study. Blood, 2018, 132, 2492-2492.	1.4	3
42	The association between health utility and joint status among people with severe haemophilia A: findings from the KAPPA register. Haemophilia, 2017, 23, e180-e187.	2.1	11
43	The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor. Thrombosis Journal, 2017, 15, 6.	2.1	32
44	Hypertension, haematuria and renal functioning in haemophilia â€“ a crossâ€sectional study in Europe. Haemophilia, 2016, 22, 248-255.	2.1	39
45	How to compare cardiovascular disease and risk factors in elderly patients with haemophilia with the general population. Haemophilia, 2016, 22, e406-16.	2.1	9
46	Evaluation of the utility of the <scp>ISTH</scp>â€<scp>BAT</scp> in haemophilia carriers: a multinational study. Haemophilia, 2016, 22, 912-918.	2.1	60
47	Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome. Rheumatology, 2016, 55, 1337-1339.	1.9	49
48	Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. Lancet Haematology,the, 2016, 3, e64-e71.	4.6	311
49	Characterization of Bleeding in Hemophilia Carriers and Comparison to Women with Type 1 Von Willebrand Disease, Type 3 Von Willebrand Disease Obligate Carriers and Controls. Blood, 2016, 128, 875-875.	1.4	0
50	Feiba Global Outcome Study (FEIBA-GO): Long-Term Real World Data on Apcc (FeibaR) in Patients with Inhibitors. First Demographic Data. Blood, 2016, 128, 5038-5038.	1.4	0
51	Presentation and management of acute coronary syndromes among adult persons with haemophilia: results of an international, retrospective, 10â€year survey. Haemophilia, 2015, 21, 589-597.	2.1	38
52	Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet, The, 2015, 385, 1653-1661.	13.7	167
53	Renal Status and Hematuria in Older Patients with Hemophilia. Blood, 2015, 126, 2290-2290.	1.4	1
54	Haemophilic arthropathy: Long-term outcomes in 107 primary total knee arthroplasties. Knee, 2014, 21, 147-150.	1.6	40

#	ARTICLE	IF	CITATIONS
55	Multicentric Study Evaluating Venous Thrombosis Among Patients with Haemophilia Undergoing Major Orthopaedic Surgery. Blood, 2014, 124, 1496-1496.	1.4	1
56	Rituximab As Second Line Treatment For Adult Immune Thrombocytopenia (ITP): A Multicentre, Randomized, Double Blind, Placebo-Controlled Study â€“ The Ritp Study (NCT00344149). Blood, 2013, 122, 449-449.	1.4	3
57	rFVIIa administered by continuous infusion during surgery in patients with severe congenital FVII deficiency. Haemophilia, 2011, 17, 764-770.	2.1	23
58	Home treatment with bypassing products in inhibitor patients: a 7.5â€year experience. Haemophilia, 2009, 15, 727-732.	2.1	17
59	Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection. FASEB Journal, 1998, 12, 79-89.	0.5	41
60	The Difference Between Platelet and Plasma FXIII Used to Study the Mechanism of Platelet Microvesicle Formation. Thrombosis and Haemostasis, 1993, 70, 681-686.	3.4	38